Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | MCOLN3 | Q8TDD5 | 3/20 | 0.64 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.64 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493045 | 0.98 | POLB (0.72) | KDM4EPOLBRAB9AVCAM1USP2 | |
| SCHEMBL15010831 | 0.85 | ALDH1A1 (0.73) | KDM4EPOLBRAB9AVCAM1USP2 | |
| SCHEMBL8049609 | 0.84 | RAB9A (0.85) | KDM4EPOLBRAB9AVCAM1USP2 | |
| SCHEMBL20526493 | 0.84 | KDM4E (0.63) | KDM4EPOLBRAB9AVCAM1USP2 | |
| SCHEMBL13489662 | 0.84 | MAPT (0.70) | KDM4EPOLBRAB9AUSP2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4274 | 0.82 | MAPT (0.68) | KDM4EPOLBRAB9AUSP2ALDH1A1 | |
| SCHEMBL16733049 | 0.82 | HSD17B10 (0.61) | KDM4EPOLBVCAM1USP2TSHR | |
| SCHEMBL14847757 | 0.81 | RAB9A (0.55) | KDM4EPOLBRAB9AVCAM1TSHR | |
| SCHEMBL25231430 | 0.80 | HSD17B10 (0.59) | KDM4EPOLBRAB9AVCAM1USP2 | |
| SCHEMBL2705461 | 0.80 | L3MBTL1 (0.83) | KDM4EPOLBUSP2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9211279-B2 | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-12-15 | — | — | US | disclosed |
| US-20150246021-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-03 | — | — | US | disclosed |
| US-9000029-B2 | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-04-07 | — | — | US | disclosed |
| US-20150057328-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-02-26 | — | — | US | disclosed |
| US-8895606-B2 | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-25 | — | — | US | disclosed |
| EP-2608787-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-20130150424-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-06-13 | — | — | US | disclosed |
| WO-2012025877-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-03-01 | — | — | WO | disclosed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057328-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | KDM4E 3175/4885POLB 4576/4885RAB9A 2429/4885 |
| US-20130150424-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | KDM4E 3175/4885POLB 4576/4885RAB9A 2429/4885 |
| US-20150246021-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | KDM4E 3117/4885POLB 4577/4885RAB9A 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.